Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
International Journal of Biological Macromolecules|November 5, 2025
ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stressYuanzhen Zhang, Xiaozhi Hu, Zhonglian Cao, et al.
ACS Biomaterials Science & Engineering|January 12, 2021
"Steel-Concrete" Inspired Biofunctional Layered Hybrid Cage for Spine Fusion and Segmental Bone ReconstructionJingzhou Yang, Yu Shrike Zhang, Pengfei Lei, et al.
Journal of Nanobiotechnology|May 19, 2022
A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver diseaseXiaozhi Hu, Jiajun Fan, Qianqian Ma, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 19, 2024
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid MetabolismYu Bai, Yanyang Nan, Tao Wu, et al.
Cell Death Discovery|January 16, 2023
Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation responseZhonglian Cao, Hui Zhao, Jiajun Fan, et al.
Frontiers in Immunology|December 22, 2022
A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in miceQianqian Ma, Xiaozhi Hu, Fangyu Liu, et al.
Immunotherapy|February 2, 2023
Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphomaYanyang Nan, Xuyao Zhang, Shaofei Wang, et al.
Pharmacological Research|November 2, 2024
Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidationXiaozhi Hu, Yanyang Nan, Yuting Zhang, et al.
Journal for Immunotherapy of Cancer|September 4, 2024
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapyYanyang Nan, Yu Bai, Xiaozhi Hu, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|April 17, 2026
Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db miceShuwen Xu, Longfei Wang, Zihan Dou, et al.
Pageof 3